Abstract
β-DIETHYLAMINOETHYL diphenylpropylacetate (SKF 525A) has been demonstrated in the rat to inhibit the metabolism of drugs both in vitro and in vivo1,2. We have demonstrated that the conversion of cortisol to a polar metabolite or metabolites by the 9,000g supernatant of the male rat liver is inhibited by the addition of SKF 525A to the incubation mixture3. The similarity between liver enzymes which metabolize drugs and those which hydroxylate steroids4 suggested the possibility that SKF 525A would inhibit the hydroxylation of cortisol in vivo. In turn, it was thought that this inhibition could manifest itself in an increase in the biological activity of administered cortisol. The administration of cortisol is known to increase the activity of rat liver tyrosine transaminase5,6. The present investigation demonstrates in the male rat a further increase in cortisol induction of tyrosine transaminase by SKF 525A.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have